Arcus Biosciences (NYSE:RCUS) Issues Quarterly Earnings Results, Misses Expectations By $0.11 EPS

Arcus Biosciences (NYSE:RCUS) posted its quarterly earnings results on Wednesday. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.11), FiscalAI reports. The company had revenue of $9.00 million during the quarter, compared to analyst estimates of $7.58 million. Arcus Biosciences had a negative net margin of 393.16% and a negative return on equity of 89.54%. The company’s revenue was down 65.4% on a year-over-year basis. During the same period in the prior year, the company earned ($1.27) earnings per share.

Arcus Biosciences Trading Up 2.2%

NYSE:RCUS opened at $19.32 on Thursday. Arcus Biosciences has a 12-month low of $17.43 and a 12-month high of $31.74. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.82 and a quick ratio of 3.82. The business has a 50 day simple moving average of $24.26 and a 200 day simple moving average of $24.58. The firm has a market capitalization of $2.46 billion, a P/E ratio of -4.95 and a beta of 1.04.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on RCUS shares. Citigroup lifted their price target on Arcus Biosciences from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Thursday, October 15th. William Blair assumed coverage on Arcus Biosciences in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Wells Fargo & Company boosted their price target on Arcus Biosciences from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Thursday, August 6th. Finally, HC Wainwright boosted their price target on Arcus Biosciences from $32.00 to $45.00 and gave the company a “buy” rating in a report on Monday, July 20th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Arcus Biosciences has an average rating of “Moderate Buy” and a consensus target price of $39.64.

Insider Buying and Selling at Arcus Biosciences

In related news, CAO Alexander Azoy sold 2,827 shares of Arcus Biosciences stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $30.00, for a total value of $84,810.00. Following the sale, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,187,430. This trade represents a 6.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.60% of the stock is currently owned by company insiders.

Key Stories Impacting Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Analysts’ average price target is reported at $39.64, well above the stock’s recent trading level. Price targets are estimates, not guarantees. Article: Arcus Biosciences Stock Has Average Target Price of $39.64 According to Analysts
• Neutral Sentiment: Arcus provided a pipeline update alongside its results. The available report excerpt mentions October HIF-2 data but does not provide enough detail to assess the update’s potential impact. Article: Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
• Negative Sentiment: Third-quarter loss was $1.00 per share, missing the cited consensus estimate of a $0.89 loss. Revenue was $9 million—above one reported estimate of $7.58 million, but down 65.4% from a year earlier. The loss did narrow from $1.27 per share in the prior-year quarter. Article: Arcus Biosciences Reports Q3 Loss

Arcus Biosciences Company Profile

Arcus Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets.